Abstract: The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said substituted benzene disulfonamides are binding to the prenyl binding pocket of PDE6? and therefore, are useful for the prophylaxis and treatment of cancer by inhibition of the binding of PDE6? to farnesylated Ras proteins and thereby, inhibition of oncogenic Ras signaling in cells.

Abstract: The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said substituted benzene disulfonamides are binding to the prenyl binding pocket of PDE6? and therefore, are useful for the prophylaxis and treatment of cancer by inhibition of the binding of PDE6? to farnesylated Ras proteins and thereby, inhibition of oncogenic Ras signaling in cells.

Abstract: The present invention relates to a crystal of a ternary complex composed of the protein 14-3-3, a ligand thereof and a fragment of Plasma Membrane ATPase (PMA) comprising the coordinates of table 4 or coordinates which differ from the coordinates of table 4 by a root mean square deviation of the C-alpha atoms of less than 3 Angstrom, wherein (a) protein 14-3-3 consists of the amino acid sequence of SEQ ID NO: 1 or of the sequence of a species homolog; (b) the ligand is Fusicocdin; (c) PMA is a C-terminal peptide of up to 15 amino acid residues in length; comprising the amino acid sequence of SEQ ID NO: 2 or comprising the sequence of a species homolog. Moreover, the invention also relates to methods for obtaining crystals of 14-3-3 in ternary complex and to methods relating to the determination of said 14-3-3 crystal coordinates.

Abstract: The present invention relates to a crystal of a ternary complex composed of the protein 14-3-3, a ligand thereof and a fragment of Plasma Membrane ATPase (PMA) comprising the coordinates of table 4 or coordinates which differ from the coordinates of table 4 by a root mean square deviation of the C-alpha atoms of less than 3 Angstrom, wherein (a) protein 14-3-3 consists of the amino acid sequence of SEQ ID NO: 1 or of the sequence of a species homolog; (b) the ligand is Fusicocdin; (c) PMA is a C-terminal peptide of up to 15 amino acid residues in length; comprising the amino acid sequence of SEQ ID NO: 2 or comprising the sequence of a species homolog. Moreover, the invention also relates to methods for obtaining crystals of 14-3-3 in ternary complex and to methods relating to the determination of said 14-3-3 crystal coordinates.